Virtual Screening of Indonesian Herbal Compounds with Neuraminidase Inhibitor Activity against N2 Influenza Virus Protein: An in silico Study

Diana Nurjanah, Fadilah Fadilah, Ni Luh Putu Indi Dharmayanti

Abstract


Background: Neuraminidase inhibitor (NAI) is one of anti-influenza drugs recommended for use by the World Health Organization (WHO). However, after treatment with NAI drugs in human, resistance to influenza antiviral drugs is begun to rise. Therefore, identification of compounds from Indonesian herbal plants as natural inhibitors of the influenza virus neuraminidase protein needs to be conducted for the development of new anti-influenza drugs.

Materials and methods: The crystal structure of the neuraminidase protein complex used in this study was obtained from the Protein Data Bank (PDB). Structure-based pharmacophore modeling was performed using LigandScout version 4.4.5 software. Indonesian herbal plant compounds were collected from the HerbalDB database. Protein and ligand processing was carried out using Autodock 4.2 software. The 3D interaction visualization was carried out with Autodock software, while 2D interaction visualization was carried out with LigPlot software. To determine the toxicity and drug-likeliness of the ligand, the test ligands that had the best docking results were predicted using SwissADME and AdmetSAR.

Results: From the virtual screening results, 24 hits were found, and five compounds had the best binding energy among the 24 tested compounds, these were pollenitin (ΔG=-7.22 kcal/mol), OPC-4:0 (ΔG=-7.11 kcal/mol), 6-hydroxykaempferol (ΔG=-7.08 kcal/mol), 5,8-dihydroxy-7,4'-dimethoxyflavone (ΔG=-7.07 kcal/mol), and 3,5,6,7-tetrahydroxy-4'-methoxyflavone (ΔG=-6.95 kcal/mol). The best five compounds were then chosen for further analysis.

Conclusion: OPC-4:0 is found to be the best compound for the NAI based on its binding energy, pharmacokinetics, toxicity, and drug-likeliness. Thus, OPC-4:0 might be a potential candidate as a NAI of HxN2 virus. 

Keywords: influenza, molecular docking, neuraminidase, resistance, virtual screening


Full Text:

PDF

References


Spackman E, Suarez D. Avian Influenza Virus. Totowa: Humana Press; 2008, CrossRef.

Perdue ML. Molecular determinants of pathogenicity for avian influenza viruses. In: Swayne DE, editor. Avian Influenza. Hoboken: John Wiley & Sons; 2008. p.23-42, CrossRef.

GISAID [Internet]. Munich; ©2008. EPIFlu [cited 2024 Mar 14]. Available from: https://platform.epicov.org/.

Honigsbaum M. Revisiting the 1957 and 1968 influenza pandemics. Lancet. 2020; 395(10240): 1824-6, CrossRef.

Linster M, Schrauwen EJA, van der Vliet S, Burke DF, Lexmond P, Bestebroer TM, et al. The molecular basis for antigenic drift of human A/H2N2 influenza viruses. J Virol. 2019; 93(8): e01907-128, CrossRef.

Sun X, Belser JA, Maines TR. Adaptation of H9N2 influenza viruses to mammalian hosts: A review of molecular markers. Viruses. 2020; 12(5): 541, CrossRef.

Peacock THP, James J, Sealy JE, Iqbal M. A global perspective on H9N2 avian influenza virus. Viruses. 2019; 11(7): 620, CrossRef.

Song W, Qin K. Human-infecting influenza A (H9N2) virus: A forgotten potential pandemic strain? Zoonoses Public Health. 2020; 67(3): 203-12, CrossRef.

Um S, Siegers JY, Sar B, Chin S, Patel S, Bunnary S, et al. Human infection with avian influenza A (H9N2) virus, Cambodia, February 2021. Emerg Infect Dis. 2021; 27(10): 2742-5, CrossRef.

Global Influenza Program [Internet]. WHO; ©2024. Cumulative Number of Confirmed Human Cases of Avian Influenza A (H5N1) Reported to WHO 2003-2023, 5 January 2023 [cited 2024 Mar 14]. Available from: https://www.who.int/.

Jonas M, Sahesti A, Murwijati T, Lestariningsih CL, Irine I, Ayesda CS, et al. Identification of avian influenza virus subtype H9N2 in chicken farms in Indonesia. Prev Vet Med. 2018; 159: 99-105, CrossRef.

Dong G, Xu C, Wang C, Wu B, Luo J, Zhang H, et al. Reassortant H9N2 influenza viruses containing H5N1-like PB1 genes isolated from black-billed magpies in Southern China. PLoS One. 2011; 6(9): e25808, CrossRef.

Ison MG. Optimizing antiviral therapy for influenza: Understanding the evidence. Expert Rev Anti Infect Ther. 2015; 13(4): 417-25, CrossRef.

Shie JJ, Fang JM. Development of effective anti-influenza drugs: Congeners and conjugates - A review. J Biomed Sci. 2019; 26(1): 84, CrossRef.

Bassetti M, Castaldo N, Carnelutti A. Neuraminidase inhibitors as a strategy for influenza treatment: Pros, cons and future perspectives. Expert Opin Pharmacother. 2019; 20(14): 1711-8, CrossRef.

Lavecchia A, Di Giovanni C. Virtual screening strategies in drug discovery: A critical review. Curr Med Chem. 2013; 20(23): 2839-60, CrossRef.

Moradi M, Golmohammadi R, Najafi A, Moosazadeh MM, Fasihi-Ramandi M, Mirnejad R. A contemporary review on the important role of in silico approaches for managing different aspects of COVID-19 crisis. Inform Med Unlocked. 2022; 28: 100862, CrossRef.

Kosasih H, Bratasena A, Pangesti K, Laras K, Samaan G. Managing seasonal influenza: Oseltamivir treatment policy in Indonesia? Acta Med Indones. 2014; 46(1): 58-65, article.

Agustiningsih A, Indalao IL, Pangesti KA, Sukowati CHC, Ramadhany R. Molecular characterization of influenza A/H3N2 virus isolated from Indonesian hajj and umrah pilgrims 2013 to 2014. Life. 2023; 13(5): 1100, CrossRef.

Pawestri HA, Nugraha AA, Hariastuti NI, Setiawaty V. Detection of neuraminidase inhibitor-resistant influenza A (H1N1)pdm09 viruses obtained from influenza surveillance in Indonesia. SAGE Open Med. 2018; 6: 2050312118818293, CrossRef.

Choi JG, Kim YS, Kim JH, Chung HS. Antiviral activity of ethanol extract of Geranii Herba and its components against influenza viruses via neuraminidase inhibition. Sci Rep. 2019; 9(1): 12132, CrossRef.

Yang XY, Liu AL, Liu SJ, Xu XW, Huang LF. Screening for neuraminidase inhibitory activity in traditional Chinese medicines used to treat influenza. Molecules. 2016; 21(9): 1138, CrossRef.

Liu J, Zu M, Chen K, Gao L, Min H, Zhuo W, et al. Screening of neuraminidase inhibitory activities of some medicinal plants traditionally used in Lingnan Chinese medicines. BMC Complement Altern Med. 2018; 18(1): 102, CrossRef.

Meli R, Morris GM, Biggin PC. Scoring functions for protein-ligand binding affinity prediction using structure-based deep learning: A review. Front Bioinform. 2022; 2: 885983, CrossRef.

Uday MS, Sachin HR. Efficiency of AUTODOCK: Insilico study of pharmaceutical drug molecules. Asian J Res Chem. 2021; 14(1): 92-6, CrossRef.

Massardi A, Bahry SS, Rahmawati NA, Shabirah CA, Pangastuti A. Bioactive compounds from Penicillium sp. inhibit antiapoptotic Bcl-2, Bcl-XL and Mcl-1: An in silico Study. Mol Cell Biomed Sci. 2023; 7(2): 81-9, CrossRef.

Stephenson I, Democratis J, Lackenby A, McNally T, Smith J, Pareek M, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis. 2009; 48(4): 389-96, CrossRef.

Bauer K, Dürrwald R, Schlegel M, Pfarr K, Topf D, Wiesener N, et al. Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008. Med Microbiol Immunol. 2012; 201(1): 61-72, CrossRef.

Hayden FG, Pavia AT. Antiviral management of seasonal and pandemic influenza. J Infect Dis. 2006; 194 Suppl 2: S119-26, CrossRef.

Hariyono P, Kotta JC, Adhipandito CF, Aprilianto E, Candaya EJ, Wahab HA, et al. A study on catalytic and non-catalytic sites of H5N1 and H1N1 neuraminidase as the target for chalcone inhibitors. Appl Biol Chem. 2021; 64(1): 69, CrossRef.

Zhu Q, Bang TH, Ohnuki K, Sawai T, Sawai K, Shimizu K. Inhibition of neuraminidase by Ganoderma triterpenoids and implications for neuraminidase inhibitor design. Sci Rep. 2015; 5: 13194, CrossRef.

Karthick V, Ramanathan K, Shanthi V, Rajasekaran R. Identification of potential inhibitors of H5N1 influenza A virus neuraminidase by ligand-based virtual screening approach. Cell Biochem Biophys. 2013; 66(3): 657-69, CrossRef.

Aliffia D, Ramadhani D, Wasityastuti W, Sari D, Kustiati U, Wihadmadyatami H, et al. Ocimum sanctum leaves prevent neuronal cell apoptosis through reduction of caspase-3 and -9 expressions and inhibition of β-amyloid oligomerization. Indones Biomed J. 2023; 15(4): 322-32, CrossRef.

Bahtiarsyah AA, Hidayati L, Wijayanti N, Nuringtyas TR. Synergistic activity of Cinnamomum burmannii (Nees & T. Nees) Blume and Aquilaria malaccensis Lamk. extracts for antidiabetic study. Indones Biomed J. 2023; 15(2): 132-40, CrossRef.

Panghiyangani R, Utami JP, Baitullah MA, Maulida ND. Molecular docking of Citrus amblycarpa active compounds against FTO, leptin, and resistin protein. Mol Cell Biomed Sci. 2023; 7(1): 38-46, CrossRef.

PubChem [Internet]. Bethesda: US National Library of Medicine; ©2024. (9R,13R)-1a,1b-dihomo-jasmonic acid [cited 2024 Mar 14]. Available from: https://pubchem.ncbi.nlm.nih.gov/.

Mahamba C, Palamuleni LG. Antimicrobial activity of sunflower (Helianthus annuus) seed for household domestic water treatment in Buhera District, Zimbabwe. Int J Environ Res Public Health. 2022; 19(9): 5462, CrossRef.

Jarocka-Karpowicz I, Markowska A. Therapeutic potential of jasmonic acid and its derivatives. Int J Mol Sci. 2021; 22(16): 8437, CrossRef.




DOI: https://doi.org/10.21705/mcbs.v8i2.468

Copyright (c) 2024 Cell and BioPharmaceutical Institute

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Indexed by:

               

                      


Cell and BioPharmaceutical Institute